Incyte Co. (NASDAQ:INCY – Get Free Report) has received a consensus rating of “Hold” from the fifteen research firms that are currently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $76.07.
Several research analysts have recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Incyte in a research note on Tuesday, February 6th. Truist Financial dropped their price target on shares of Incyte from $91.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Stifel Nicolaus increased their price objective on Incyte from $67.00 to $68.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. JMP Securities downgraded Incyte from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 14th. Finally, BMO Capital Markets increased their price target on Incyte from $58.00 to $64.00 and gave the company a “market perform” rating in a research note on Wednesday, February 14th.
View Our Latest Research Report on Incyte
Hedge Funds Weigh In On Incyte
Incyte Price Performance
Shares of NASDAQ:INCY opened at $52.72 on Friday. Incyte has a one year low of $50.27 and a one year high of $75.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.55 and a quick ratio of 3.36. The company has a market cap of $11.84 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 1.24 and a beta of 0.65. The firm has a 50 day simple moving average of $57.65 and a 200 day simple moving average of $57.99.
Incyte (NASDAQ:INCY – Get Free Report) last released its quarterly earnings data on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business earned $0.44 EPS. The company’s revenue was up 9.3% compared to the same quarter last year. Research analysts predict that Incyte will post 3.84 earnings per share for the current fiscal year.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Stories
- Five stocks we like better than Incyte
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- United Airlines Soars on Earnings Beat
- Conference Calls and Individual Investors
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.